---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-045215"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2025-10-16T23:59:59+00:00"
generated_at: "2026-05-17T03:34:03.418375+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences ends AIH program after FDA setback, begins strategic review

## Summary
- FDA cancelled Type C meeting for zetomipzomib in autoimmune hepatitis; requires PK study causing ~2-year delay and 48-hour in-unit monitoring.
- Company to explore strategic alternatives, retain TD Cowen; restructuring includes workforce reduction and cost containment.
- Preliminary cash, equivalents and marketable securities of $90.2M as of Sep 30, 2025 (unaudited).
- Rights plan amended to extend expiration to after 2026 annual meeting (or 2027 if ratified); not in response to takeover threat.
- PORTOLA final data still to be presented at The Liver Meeting Nov 10, 2025.

## SEC filing metadata
- accession: 0001628280-25-045215
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2025-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.03, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000162828025045215/0001628280-25-045215-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000162828025045215/kzr-20251016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-045215
- JSON: https://secwatch.observer/filing/0001628280-25-045215.json
- Plain text: https://secwatch.observer/filing/0001628280-25-045215.txt

## Key facts
- Equity Issuances
  Kezar Life Sciences, Inc. issued securities.
  source text: On October 16, 2025, the Company entered into Amendment No. 2 (the “Amendment”) to the Rights Agreement, dated as of October 17, 2024, as amended on December 3, 2024, by and between the Company and Computershare Trust Company, N.A., as rights agent (as amended, the “Rights Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000162828025045215/0001628280-25-045215-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.